Page last updated: 2024-12-11
binodenoson
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9576912 |
| MeSH ID | M0267103 |
Synonyms (33)
| Synonym |
|---|
| sha-174 |
| mre0470 |
| 2-(2-(cyclohexylmethylene)diazanyl)-9-beta-d-ribofuranosyl-9h-purin-6-amine |
| binodenoson [usan] |
| mre-0470 |
| 2-((cyclohexylmethylene)hydrazino)adenosine |
| adenosine, 2-((cyclohexylmethylene)hydrazino)- |
| wrc 0470 |
| wrc-0470 |
| binodenoson |
| lja4m1l5lg , |
| binodenoson [usan:inn:ban] |
| unii-lja4m1l5lg |
| D03120 |
| binodenoson (usan/inn) |
| 144348-08-3 |
| wrc0470 |
| 2-(2-(cyclohexylmethylene)diazanyl)-9-.beta.-d-ribofuranosyl-9h-purin-6-amine |
| binodenoson [inn] |
| binodenoson [mi] |
| 2-((e)-(cyclohexylmethylene)hydrazino)adenosine |
| DB04853 |
| corvue |
| mre 0470; sha 174; sha 211; wrc 0470 |
| bdbm50230152 |
| (2r,3r,4s,5r)-2-(6-amino-2-(2-(cyclohexylmethylene)hydrazinyl)-9h-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol |
| MS-26528 |
| (2r,3r,4s,5r)-2-[6-amino-2-[(2e)-2-(cyclohexylmethylidene)hydrazinyl]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol |
| adenosine, 2-[2-(cyclohexylmethylene)hydrazinyl]- |
| HY-106450 |
| DTXSID60869938 |
| CS-0025848 |
| AKOS040759844 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " There were no serious adverse events." | ( Pharmacokinetics and safety of binodenoson after intravenous dose escalation in healthy volunteers. Barrett, RJ; Johnson, J; Lamson, MJ; Smith, WB, ) | 0.42 |
| " Secondary safety end points were changes from preinjection measure in forced expiratory volume in 1 second, forced vital capacity, and forced expiratory flow during the middle 50% of the forced vital capacity; vital signs; pulse oximetry; and adverse events." | ( Safety of binodenoson, a selective adenosine A2A receptor agonist vasodilator pharmacological stress agent, in healthy subjects with mild intermittent asthma. Barrett, RJ; Busse, WW; Katial, RK; Lockey, RF; McFadden, ER; Murray, JJ; Pixton, GC; Schwartz, LB; Weiler, JM, 2009) | 0.76 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " Binodenoson exhibited linear pharmacokinetics as indicated by a dose-proportional increase in peak concentration (C max ) and area under the concentration-time curve (AUC)." | ( Pharmacokinetics and safety of binodenoson after intravenous dose escalation in healthy volunteers. Barrett, RJ; Johnson, J; Lamson, MJ; Smith, WB, ) | 1.33 |
Dosage Studied
The purpose of this study was to define binodenoson dosing regimens that produce coronary hyperemia comparable to those of adenosine. 240 patients underwent 2 single photon emission computed tomographic (SPECT) imaging studies in random order.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a multicenter, randomized, single-blind, 2-arm crossover trial, 240 patients underwent 2 single photon emission computed tomographic (SPECT) imaging studies in random order, first after pharmacological stress with adenosine and a second study with the selective adenosine A2A receptor agonist binodenoson, using 1 of 4 dosing regimens." | ( Randomized, controlled dose-ranging study of the selective adenosine A2A receptor agonist binodenoson for pharmacological stress as an adjunct to myocardial perfusion imaging. Barrett, RJ; Chai, A; Coleman, PS; DiCarli, M; Dilsizian, V; Gibbons, RJ; Hachamovitch, R; Heller, GV; Hinchman, D; Johnson, JR; Udelson, JE; Wackers, FJ, 2004) | 0.72 |
| "The purpose of this study was to define binodenoson dosing regimens that produce coronary hyperemia comparable to those of adenosine and that are tolerated well by patients." | ( Coronary circulation responses to binodenoson, a selective adenosine A2A receptor agonist. Bach, RG; Barrett, RJ; Dib, N; Hodgson, JM; Kern, MJ, 2007) | 0.89 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (7)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Adenosine receptor A3 | Homo sapiens (human) | Ki | 0.6195 | 0.0000 | 0.9306 | 10.0000 | AID1138018; AID727465; AID727469 |
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | Ki | 0.2700 | 0.0001 | 1.2092 | 9.9700 | AID727603 |
| Adenosine receptor A2a | Homo sapiens (human) | Ki | 0.2322 | 0.0000 | 1.0609 | 9.7920 | AID1138011; AID1201434; AID647885; AID727459; AID727603 |
| Adenosine receptor A2b | Homo sapiens (human) | Ki | 220.0000 | 0.0002 | 1.6352 | 10.0000 | AID727460; AID727601 |
| Adenosine receptor A1 | Homo sapiens (human) | Ki | 32.0563 | 0.0002 | 0.9316 | 10.0000 | AID1138015; AID727464; AID727607 |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | Ki | 430.0000 | 0.0000 | 0.2018 | 6.4240 | AID727460 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Activation Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Adenosine receptor A2a | Homo sapiens (human) | EC50 (µMol) | 0.0003 | 0.0003 | 0.7081 | 10.0000 | AID30508 |
| Adenosine receptor A2b | Homo sapiens (human) | EC50 (µMol) | 50.0001 | 0.0003 | 0.9461 | 10.0000 | AID1138014; AID30508 |
| Adenosine receptor A1 | Cavia porcellus (domestic guinea pig) | EC50 (µMol) | 3.5481 | 0.0126 | 1.9338 | 5.6234 | AID32149 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (105)
Molecular Functions (16)
Ceullar Components (18)
Bioassays (25)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1138036 | Selectivity ratio of Ki for human recombinant adenosine receptor A2b to Ki for human recombinant adenosine receptor A2a | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9 | Adenosine A2A receptor as a drug discovery target. |
| AID727604 | Displacement of [3H]CGS21680 from adenosine A2A receptor in rat brain striatal membrane after 60 mins by liquid scintillation counting analysis | 2013 | Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2 | Synthesis and structure-activity relationships of 2-hydrazinyladenosine derivatives as A(2A) adenosine receptor ligands. |
| AID727601 | Displacement of [3H]PSB-603 from human recombinant adenosine A2B receptor expressed in CHO cells after 75 mins by liquid scintillation counting analysis | 2013 | Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2 | Synthesis and structure-activity relationships of 2-hydrazinyladenosine derivatives as A(2A) adenosine receptor ligands. |
| AID727459 | Displacement of [3H]CGS21680 from human recombinant adenosine A2A receptor expressed in HEK cells after 60 mins by liquid scintillation counting | 2013 | Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2 | Synthesis and structure-activity relationships of 2-hydrazinyladenosine derivatives as A(2A) adenosine receptor ligands. |
| AID727600 | Displacement of [3H]PSB-603 from human recombinant adenosine A2B receptor expressed in CHO cells at 10 uM after 75 mins by liquid scintillation counting analysis | 2013 | Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2 | Synthesis and structure-activity relationships of 2-hydrazinyladenosine derivatives as A(2A) adenosine receptor ligands. |
| AID727607 | Displacement of [3H]CCPA from human recombinant adenosine A1 receptor expressed in CHO cells 90 mins by liquid scintillation counting analysis | 2013 | Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2 | Synthesis and structure-activity relationships of 2-hydrazinyladenosine derivatives as A(2A) adenosine receptor ligands. |
| AID32461 | Selectivity ratio for A1 and A2 receptors. | 1992 | Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24 | 2-(N'-alkylidenehydrazino)adenosines: potent and selective coronary vasodilators. |
| AID727464 | Displacement of [3H]CCPA from human recombinant adenosine A1 receptor | 2013 | Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2 | Synthesis and structure-activity relationships of 2-hydrazinyladenosine derivatives as A(2A) adenosine receptor ligands. |
| AID1138020 | Selectivity ratio of Ki for human recombinant adenosine A1 receptor to Ki for human recombinant adenosine receptor A2a | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9 | Adenosine A2A receptor as a drug discovery target. |
| AID1138037 | Systemic vasodilation in rat | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9 | Adenosine A2A receptor as a drug discovery target. |
| AID647885 | Binding affinity to A2A adenosine receptor | 2012 | Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1 | Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A₂A adenosine receptor. |
| AID1138018 | Binding affinity to human recombinant adenosine A3 receptor | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9 | Adenosine A2A receptor as a drug discovery target. |
| AID727608 | Displacement of [3H]CCPA from adenosine A1 receptor in rat brain cortical membrane after 90 mins by liquid scintillation counting analysis | 2013 | Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2 | Synthesis and structure-activity relationships of 2-hydrazinyladenosine derivatives as A(2A) adenosine receptor ligands. |
| AID727469 | Displacement of [3H]NECA from human recombinant adenosine A3 receptor expressed in CHO cells after 180 mins by liquid scintillation counting analysis | 2013 | Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2 | Synthesis and structure-activity relationships of 2-hydrazinyladenosine derivatives as A(2A) adenosine receptor ligands. |
| AID32149 | In vitro prolonging of the stimulus-QRS interval in guinea pig heart. | 1992 | Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24 | 2-(N'-alkylidenehydrazino)adenosines: potent and selective coronary vasodilators. |
| AID30508 | In vitro effect on coronary vasodilation in guinea pig heart. | 1992 | Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24 | 2-(N'-alkylidenehydrazino)adenosines: potent and selective coronary vasodilators. |
| AID1138011 | Binding affinity to human recombinant adenosine receptor A2a | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9 | Adenosine A2A receptor as a drug discovery target. |
| AID727603 | Displacement of [3H]CGS21680 from human recombinant adenosine A2A receptor expressed in HEK cells | 2013 | Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2 | Synthesis and structure-activity relationships of 2-hydrazinyladenosine derivatives as A(2A) adenosine receptor ligands. |
| AID1138015 | Binding affinity to human recombinant adenosine A1 receptor | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9 | Adenosine A2A receptor as a drug discovery target. |
| AID727465 | Displacement of [3H]NECA from human recombinant adenosine A3 receptor | 2013 | Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2 | Synthesis and structure-activity relationships of 2-hydrazinyladenosine derivatives as A(2A) adenosine receptor ligands. |
| AID727460 | Displacement of [3H]PSB-603 from human recombinant adenosine A2B receptor | 2013 | Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2 | Synthesis and structure-activity relationships of 2-hydrazinyladenosine derivatives as A(2A) adenosine receptor ligands. |
| AID727463 | Selectivity ratio of Ki for human recombinant adenosine A2A receptor to Ki for adenosine A2A receptor in rat brain striatal membrane | 2013 | Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2 | Synthesis and structure-activity relationships of 2-hydrazinyladenosine derivatives as A(2A) adenosine receptor ligands. |
| AID1138014 | Agonist activity at human recombinant adenosine receptor A2b by cAMP assay | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9 | Adenosine A2A receptor as a drug discovery target. |
| AID1138038 | In vivo adenosine A1 receptor-mediated decrease in heart rate | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9 | Adenosine A2A receptor as a drug discovery target. |
| AID1201434 | Binding affinity to human adenosine A2A receptor | 2015 | Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7 | Design, synthesis, and biological evaluation of novel 2-((2-(4-(substituted)phenylpiperazin-1-yl)ethyl)amino)-5'-N-ethylcarboxamidoadenosines as potent and selective agonists of the A2A adenosine receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (15)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (26.67) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 16.66
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.66) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (25.00%) | 5.53% |
| Reviews | 2 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (62.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Clinical Trials (2)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Vasodilator Induced Stress In CONcordance With Adenosine (VISION-302) [NCT00944294] | Phase 3 | 419 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| Vasodilator Induced Stress In CONcordance With Adenosine (VISION-305) [NCT00944970] | Phase 3 | 578 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||